PedAM
Pediatric Disease Annotations & Medicines
| Disease | psoriasis |
| Phenotype | C0028754|obesity |
| Sentences | 29 |
| PubMedID- 21492252 | obesity is associated with psoriasis and contributes significantly to the increased cardiovascular risk in these patients. |
| PubMedID- 23848131 | Objectives: to evaluate the prevalence of overweight and obesity in patients with moderate-to-severe psoriasis compared to the general population and to assess the relationship between body mass index (bmi) and the risk of discontinuing treatment. |
| PubMedID- 24750404 | psoriasis is associated with comorbidity including obesity, insulin resistance and diabetes mellitus type 2. |
| PubMedID- 23291856 | psoriasis is associated with obesity accompanied by insulin resistance. |
| PubMedID- 24556829 | psoriasis is associated with obesity and other cardiovascular risk factors including endothelial dysfunction. |
| PubMedID- 24474099 | A descriptive and prospective study was conducted to assess the occurrence ofdyslipidemia and obesity in patients with psoriasis treated at a reference outpatientdermatology clinic, during the period between september 2011 and june 2012. theinclusion of patients and sample size were established through spontaneous demand. |
| PubMedID- 22584116 | Additionally, it is now well established that obesity is associated with psoriasis [12]. |
| PubMedID- 22120603 | Objectives: to compare obesity among individuals with psa, psoriasis (pso), ra and the general population (n), and identify correlates of obesity among individuals with pso and psa. |
| PubMedID- 25381984 | psoriasis is frequently associated with obesity, which may favor the development of hyperuricemia. |
| PubMedID- 26054710 | Numerous reports have shown that psoriasis is associated with obesity and leptin. |
| PubMedID- 22121277 | Used the general practice research database and found higher rates of diabetes mellitus, hypertension, hyperlipidemia, obesity, and smoking in patients with psoriasis than in controls. |
| PubMedID- 23208415 | Using random-effects meta-analysis, the pooled odds ratio (or) for obesity among patients with psoriasis was 1.66 (95% confidence interval (ci) 1.46–1.89) compared with those without psoriasis. |
| PubMedID- 23110708 | Background: chronic plaque psoriasis is associated with obesity, which is a metabolic and inflammatory disorder. |
| PubMedID- 25092612 | Moreover, obesity worsens the course of ra, sle, ibd, psoriasis and psa, and impairs the treatment response of ra, ibd, psoriasis and psa. |
| PubMedID- 25599394 | Subsequently, a series of multiple studies reported a higher risk for various cardiometabolic traits (including hypertension, t2d, hyperlipidemia, hypercholesterolemia and obesity) in patients with psoriasis, in particular those with severe and widespread forms (kimball and wu, 2009; langan et al., 2012; yeung et al., 2013). |
| PubMedID- 24592364 | Apart from the predictable association of psoriasis with obesity and metabolic syndrome, a detailed history was taken from each patient regarding involved or deteriorating factors (bacterial infections, human immunodeficiency virus infection, pregnancy, hypocalcemia and causative drug consumption including terbinafine, non-steroidal anti-inflammatory drugs, anti-malarias, angiotensin-converting enzyme inhibitors, lithium, interferon [ifn] and beta blockers). |
| PubMedID- 20034760 | Environmental risk factors including streptococcal pharyngitis, stressful life events, low humidity, drugs, hiv infection, trauma, smoking and obesity have been associated with psoriasis and psa. |
| PubMedID- 26202333 | Conclusions: the prevalence of obesity in patients with psoriasis is higher than in the normal population. |
| PubMedID- 26271963 | Objective: the objective of this systematic review is to determine the association of obesity with psoriasis severity. |
| PubMedID- 20415822 | Not only the obesity may be associated with higher psoriasis incidence and activity, and prevalence of obesity-related syndromes, but it may also influence the therapeutic approach to disease and the clinical response to systemic treatment. |
| PubMedID- 19887761 | Background: psoriasis is associated with obesity and metabolic syndrome. |
| PubMedID- 22356630 | Both conditions are likely to also interact at a functional level because obesity and the up-regulation of pro-inflammatory mediators in psoriasis appear to influence adipocyte homoeostasis, inducing non-professional immune functions. |
| PubMedID- 24406087 | obesity is associated with psoriasis and poses a significant obstacle to psoriasis management. |
| PubMedID- 22691169 | Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. |
| PubMedID- 26366154 | The aim of this study was to evaluate the metabolic syndrome (ms) and its components (insulin resistance, atherogenic dyslipidaemia, abdominal obesity and hypertension) in patients with psoriasis aged 30 to 49 years compared to the adult poles, who participated in the natpol 2011 study in the same age group. |
| PubMedID- 24095656 | However, such a remarkable association of abdominal obesity with late onset psoriasis may suggest that obesity can be one of the acquired factors that may predispose for the development of psoriasis in the elderly. |
| PubMedID- 23843781 | Recently, screening using hemoglobin a1c for psoriasis patients with overweight or obesity has been suggested [18]. |
| PubMedID- 22113483 | Or 1.14 (95% ci 1.03-1.27), 34% increase in obesity with moderate psoriasis, adj. |
| PubMedID- 26015779 | On the genetic basis, the most important susceptibility locus for psoriasis, hla-cw6, is associated with obesity [12, 14]. |
Page: 1